CXCL8 and fibrosis: For the CXCL8 plasma concentration measurement, 78 aLTRs were included: 18 (23.1%) patients with NHR, 11 (14.1%) patients with clinTCMR, 34 (43.6%) patients with subTCMR, and 15 (19.2%) patients with other conditions (4, possible chronic antibody-mediated rejection; 4, indeterminate for TCMR according to Banff criteria [RAI score = 2]; 3, steatotic liver disease; 2, unspecific hepatitis; 1 possible drug-induced liver injury; 1, moderate fibrosis).